Abstract：Diabetes Osteoporosis（DOP） is chronic complication of diatetes mellitus(DM) in skeletal system, which may be caused by many possible factors, including osmotic diuresis, accumulation of advanced glycosylation end products (AGEs) ,shortage of insulin, low effect of the insulin-like growth factor -1 (IGF-1), impacts of other diabetic complications, and side effects of anti-diabetic drugs. Because of the high morbidty and serious consequences, clinicians and patients should pay more attention to DOP.
应大文, 刘芳. 糖尿病与骨质疏松的相关性研究进展[J]. 实用预防医学, 2015, 22(10): 1275-1277.
Ying Dawen, LIU Fang. The association study of diabetic mellitus and osteoporosis. , 2015, 22(10): 1275-1277.
[1] 张智海, 刘忠厚, 石少辉, 等. 中国大陆地区以-2.5SD为诊断的骨质疏松症发病率文献回顾性研究[J]. 中国骨质疏松杂志, 2015,(01):1-7+24. [2] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013,310(9):948-959. [3] Abdulameer SA, Sulaiman SA, Hassali MA, et al. Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?[J]. Patient Prefer Adherence, 2012,6:435-448. [4] Jackuliak P, Payer J, et al. Osteoporosis, fractures, and diabetes[J]. Int J Endocrinol, 2014,2014:820615. [5] Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies[J]. Eur J Epidemiol, 2012,27(5):319-332. [6] Oei L, Zillikens MC, Dehghan A, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study[J]. Diabetes Care, 2013,36(6):1619-1628. [7] Melton LJ 3rd, Riggs BL, Leibson CL, et al. A bone structural basis for fracture risk in diabetes[J]. J Clin Endocrinol Metab, 2008,93(12):4804-4809. [8] Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2010,95(11):5045-5055. [9] Dennison EM, Syddall HE, Aihie SA, et al. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance?[J]. Diabetologia, 2004,47(11):1963-1968. [10] Koh WP, Wang R, Ang LW, et al. Diabetes and risk of hip fracture in the Singapore Chinese Health Study[J]. Diabetes Care, 2010,33(8):1766-1770. [11] Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus[J]. Osteoporos Int, 2010,21(2):195-214. [12] Sanguineti R, Storace D, Monacelli F, et al. Pentosidine effects on human osteoblasts in vitro[J]. Ann N Y Acad Sci, 2008,1126:166-172. [13] Stolzing A, Sellers D, Llewelyn O, et al. Diabetes induced changes in rat mesenchymal stem cells[J]. Cells Tissues Organs, 2010,191(6):453-465. [14] Yang K, Wang XQ, He YS, et al. Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells[J]. Cardiovasc Diabetol, 2010,9:66. [15] Okazaki K, Yamaguchi T, Tanaka K, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis[J]. Calcif Tissue Int, 2012,91(4):286-296. [16] Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus[J]. Osteoporos Int, 2010,21(2):195-214. [17] Dong XN, Qin A, Xu J, et al. In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption[J]. Bone, 2011,49(2):174-183. [18] Sealand R, Razavi C, Adler RA. Diabetes mellitus and osteoporosis[J]. Curr Diab Rep, 2013,13(3):411-418. [19] S Kurra ES. Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures[J]. Diabetes Metab Res Rev, 2011,27(5):430-435. [20] Greco EA, Fornari R, Rossi F, et al. Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index[J]. Int J Clin Pract, 2010,64(6):817-820. [21] PF Shan XPW, H Zhang XZC, Gu W. Bone mineral density and its relationship with body mass index in postmenopausal women with type 2 diabetes mellitus in mainland China[J]. J Bone Miner Metab, 2009,27(2):190-197. [22] JM Li AMS. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology[J]. Am J Physiol Regul Integr Comp Physiol, 2004,287(5): R1014-30. [23] 王晓华. 长沙地区健康体检人群跟骨骨密度测量结果及影响因素分析[J]. 实用预防医学, 2014, 21(10): 1272-1274. [24] Pollycove R, Simon JA. Osteoporosis: screening and treatment in women[J]. Clin Obstet Gynecol, 2012,55(3):681-691. [25] 张智海, 刘忠厚, 李娜, 等. 中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J]. 中国骨质疏松杂志, 2014,(09):1007-1010. [26] Kurra S, Fink DA, Siris ES. Osteoporosis-associated fracture and diabetes[J]. Endocrinol Metab Clin North Am, 2014,43(1):233-243. [27] Zhang J, Wang R, Zhao YL, et al. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis[J]. Asian Pac J Trop Med, 2012,5(9):743-748. [28] Li M, Zhang ZL, Liao EY, et al. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis[J]. Menopause, 2013,20(1):72-78. [29] McClung MR, Zanchetta JR, Racewicz A, et al. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data[J]. Osteoporos Int, 2013,24(1):293-299.
2015, Vol. 22 
